Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142971 | 0.79 | HDAC1 (0.46) | HDAC1HDAC2ALDH1A1 | |
| SCHEMBL20078111 | 0.77 | HDAC1 (0.47) | ESR1ESR2HDAC1HDAC2ABHD6 | |
| SCHEMBL20364260 | 0.77 | ESR1 (0.44) | ESR1ESR2ABHD6 | |
| SCHEMBL18379795 | 0.76 | NR1H2 (0.48) | ESR2HDAC1HDAC2 | |
| SCHEMBL20078110 | 0.76 | HSP90AA1 (0.52) | ESR1ESR2HDAC1HDAC2ABHD6 | |
| SCHEMBL25045623 | 0.76 | HDAC1 (0.36) | HDAC1HDAC2 | |
| SCHEMBL25202681 | 0.73 | ESR1 (0.46) | ESR1ESR2ABHD6HDAC8HDAC6 | |
| SCHEMBL20364261 | 0.72 | ESR1 (0.40) | ESR1ESR2 | |
| SCHEMBL25604134 | 0.71 | ABHD6 (0.56) | ESR1ESR2ABHD6 | |
| SCHEMBL7786861 | 0.70 | ESR1 (0.53) | ESR1ESR2ABHD6HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | ESR1 4856/4885ESR2 3923/4885HDAC1 2/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | ESR1 4856/4885ESR2 3923/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.